pharma · Ulcerative colitis · central nervous system (CNS) lymphomas · RANI
Rani Therapeutics Holdings
Rani Therapeutics is a pharma organization headquartered in San Jose, USA. It trades on NYSE under ticker RANI. Primary therapeutic focus areas include Ulcerative colitis, central nervous system (CNS) lymphomas, Obesity.
San Jose, USA HQ
2012 Founded
99 Employees
Public company Type
RANI · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Jose, USA
- Founded
- 2012
- Employees
- 99
- Programs
- 7
- Drugs
- 12
- Patents
- 148
Berubicin hydrochloride
Phase 2 · small molecule · central nervous system (CNS) lymphomas
Berubicin hydrochloride for central nervous system (CNS) lymphomas is a Phase 2 program (small_molecule) at Rani Therapeutics Holdings with 1 ClinicalTrials.gov record(s).
Internal code BER-PUM-01
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Rani Therapeutics Holdings
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- central nervous system (CNS) lymphomas
- Status
- active
- Trials
- 1